348 related articles for article (PubMed ID: 11779037)
1. Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effects.
Wallace MJ; Wiley JL; Martin BR; DeLorenzo RJ
Eur J Pharmacol; 2001 Sep; 428(1):51-7. PubMed ID: 11779037
[TBL] [Abstract][Full Text] [Related]
2. Activation of the cannabinoid type-1 receptor mediates the anticonvulsant properties of cannabinoids in the hippocampal neuronal culture models of acquired epilepsy and status epilepticus.
Blair RE; Deshpande LS; Sombati S; Falenski KW; Martin BR; DeLorenzo RJ
J Pharmacol Exp Ther; 2006 Jun; 317(3):1072-8. PubMed ID: 16469864
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of small intestinal secretion by cannabinoids is CB1 receptor-mediated in rats.
Tyler K; Hillard CJ; Greenwood-Van Meerveld B
Eur J Pharmacol; 2000 Dec; 409(2):207-11. PubMed ID: 11104836
[TBL] [Abstract][Full Text] [Related]
4. Signaling pathways from cannabinoid receptor-1 activation to inhibition of N-methyl-D-aspartic acid mediated calcium influx and neurotoxicity in dorsal root ganglion neurons.
Liu Q; Bhat M; Bowen WD; Cheng J
J Pharmacol Exp Ther; 2009 Dec; 331(3):1062-70. PubMed ID: 19752241
[TBL] [Abstract][Full Text] [Related]
5. Effects of cannabinoid receptor agonist and antagonist ligands on production of inflammatory cytokines and anti-inflammatory interleukin-10 in endotoxemic mice.
Smith SR; Terminelli C; Denhardt G
J Pharmacol Exp Ther; 2000 Apr; 293(1):136-50. PubMed ID: 10734163
[TBL] [Abstract][Full Text] [Related]
6. Milk intake and survival in newborn cannabinoid CB1 receptor knockout mice: evidence for a "CB3" receptor.
Fride E; Foox A; Rosenberg E; Faigenboim M; Cohen V; Barda L; Blau H; Mechoulam R
Eur J Pharmacol; 2003 Feb; 461(1):27-34. PubMed ID: 12568912
[TBL] [Abstract][Full Text] [Related]
7. The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy.
Wallace MJ; Blair RE; Falenski KW; Martin BR; DeLorenzo RJ
J Pharmacol Exp Ther; 2003 Oct; 307(1):129-37. PubMed ID: 12954810
[TBL] [Abstract][Full Text] [Related]
8. Cannabinoid and nitric oxide signaling interplay in the modulation of hippocampal hyperexcitability: Study on electrophysiological and behavioral models of temporal lobe epilepsy in the rat.
Carletti F; Gambino G; Rizzo V; Ferraro G; Sardo P
Neuroscience; 2015 Sep; 303():149-59. PubMed ID: 26135674
[TBL] [Abstract][Full Text] [Related]
9. Differences in the relative potency of SR 141716A and AM 251 as antagonists of various in vivo effects of cannabinoid agonists in C57BL/6J mice.
McMahon LR; Koek W
Eur J Pharmacol; 2007 Aug; 569(1-2):70-6. PubMed ID: 17553486
[TBL] [Abstract][Full Text] [Related]
10. Cannabinoids decrease acetylcholine release in the medial-prefrontal cortex and hippocampus, reversal by SR 141716A.
Gessa GL; Casu MA; Carta G; Mascia MS
Eur J Pharmacol; 1998 Aug; 355(2-3):119-24. PubMed ID: 9760025
[TBL] [Abstract][Full Text] [Related]
11. Effect of chronic administration of R-(+)-[2,3-Dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate (WIN55,212-2) or delta(9)-tetrahydrocannabinol on cannabinoid receptor adaptation in mice.
Sim-Selley LJ; Martin BR
J Pharmacol Exp Ther; 2002 Oct; 303(1):36-44. PubMed ID: 12235230
[TBL] [Abstract][Full Text] [Related]
12. Discriminative stimulus effects of the cannabinoid CB1 antagonist SR 141716A in rhesus monkeys pretreated with Delta9-tetrahydrocannabinol.
McMahon LR
Psychopharmacology (Berl); 2006 Oct; 188(3):306-14. PubMed ID: 16953389
[TBL] [Abstract][Full Text] [Related]
13. Antiemetic and motor-depressive actions of CP55,940: cannabinoid CB1 receptor characterization, distribution, and G-protein activation.
Darmani NA; Sim-Selley LJ; Martin BR; Janoyan JJ; Crim JL; Parekh B; Breivogel CS
Eur J Pharmacol; 2003 Jan; 459(1):83-95. PubMed ID: 12505537
[TBL] [Abstract][Full Text] [Related]
14. Characterization of cannabinoid agonists and apparent pA2 analysis of cannabinoid antagonists in rhesus monkeys discriminating Delta9-tetrahydrocannabinol.
McMahon LR
J Pharmacol Exp Ther; 2006 Dec; 319(3):1211-8. PubMed ID: 16943255
[TBL] [Abstract][Full Text] [Related]
15. Modulation of cytokine responses in Corynebacterium parvum-primed endotoxemic mice by centrally administered cannabinoid ligands.
Smith SR; Terminelli C; Denhardt G
Eur J Pharmacol; 2001 Aug; 425(1):73-83. PubMed ID: 11672577
[TBL] [Abstract][Full Text] [Related]
16. Evidence for a physiological role of endocannabinoids in the modulation of seizure threshold and severity.
Wallace MJ; Martin BR; DeLorenzo RJ
Eur J Pharmacol; 2002 Oct; 452(3):295-301. PubMed ID: 12359270
[TBL] [Abstract][Full Text] [Related]
17. The cannabinoid CB1 receptor antagonist SR 141716A reverses the antiemetic and motor depressant actions of WIN 55, 212-2.
Darmani NA
Eur J Pharmacol; 2001 Oct; 430(1):49-58. PubMed ID: 11698062
[TBL] [Abstract][Full Text] [Related]
18. SR141716A is an inverse agonist at the human cannabinoid CB1 receptor.
Landsman RS; Burkey TH; Consroe P; Roeske WR; Yamamura HI
Eur J Pharmacol; 1997 Sep; 334(1):R1-2. PubMed ID: 9346339
[TBL] [Abstract][Full Text] [Related]
19. The role of cannabinoid receptors in intestinal motility, defaecation and diarrhoea in rats.
Izzo AA; Mascolo N; Pinto L; Capasso R; Capasso F
Eur J Pharmacol; 1999 Nov; 384(1):37-42. PubMed ID: 10611417
[TBL] [Abstract][Full Text] [Related]
20. Cannabinoid modulation of intestinal propulsion in mice.
Colombo G; Agabio R; Lobina C; Reali R; Gessa GL
Eur J Pharmacol; 1998 Feb; 344(1):67-9. PubMed ID: 9570450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
